- Home
- TYL vs BIIB Comparison
TYL vs BIIB Comparison
Compare TYL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TYL | BIIB |
|---|---|---|
| Founded | 1966 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 24.2B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | TYL | BIIB |
|---|---|---|
| Price | $461.32 | $176.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 22 |
| Target Price | ★ $652.82 | $177.40 |
| AVG Volume (30 Days) | 411.3K | ★ 2.5M |
| Earning Date | 02-11-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.32 | N/A |
| EPS | 7.19 | ★ 10.97 |
| Revenue | $2,298,292,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $10.91 | $3.58 |
| Revenue Next Year | $8.81 | N/A |
| P/E Ratio | $64.28 | ★ $15.93 |
| Revenue Growth | ★ 10.62 | 4.77 |
| 52 Week Low | $445.64 | $110.04 |
| 52 Week High | $661.31 | $185.17 |
Technical Indicators
Market Signals| Indicator | TYL | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 57.23 |
| Support Level | $447.35 | $168.56 |
| Resistance Level | $469.97 | $177.29 |
| Average True Range (ATR) | 9.57 | 4.81 |
| MACD | 1.93 | -1.03 |
| Stochastic Oscillator | 59.48 | 53.27 |
Price Performance
Historical ComparisonAbout TYL Tyler Technologies Inc.
Tyler Technologies provides a full suite of software solutions and services that address the needs of cities, counties, schools, courts and other local government entities. The company's three core products are Munis, which is the core ERP system, Odyssey, which is the court management system, or CMS, and payments. The company also provides a variety of add-on modules and offers outsourced property tax assessment services.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).